A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

Recruiting now · Phase 1

Conditions studied: Myelodysplastic Syndrome (MDS)

In brief

\[Tolerability Assessment Part\] The purpose is to identify the doses of the oral azacitidine(AZA) formulations and cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA injection at 75 mg/m2. \[Expansion Assessment Part\] The purpose is to compare the total AUC for AZA after administration of ASTX030 with that after administration of AZA injection at 75 mg/m2.

Key facts

Study ID

NCT04608110

Run by

Taiho Pharmaceutical Co., Ltd.

People needed

59

Starts

2020-10-30

Expected to finish

2028-01-01

Last updated by the study team

2026-08-10

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• [Tolerability Assessment Part】
• Patients aged 20 years or older
• Patients with a diagnosis of MDS (refractory anemia [RA], refractory anemia with ringed sideroblasts [RARS], refractory anemia with excess blasts [RAEB], refractory anemia with excess blasts in transformation [RAEB-T], or chronic myelomonocytic leukemia [CMML]) according to the French-American-British (FAB) classification. Low-risk patients who fall under the risk category of low or intermediate-1 (Int-1) based on the International Prognostic Scoring System (IPSS) can be enrolled only if they are unlikely to respond to any other treatment or if they are currently being treated with AZA injection.
• Patients with an ECOG PS score of 0 or 1
• Patients with adequate organ function as indicated below
• Hepatic function: All of the following criteria must be satisfied
• Total bilirubin ≤ 2.0 × upper limit of normal (ULN)
• Aspartate aminotransferase (AST) ≤ 2.5 × ULN
• Alanine aminotransferase (ALT) ≤ 2.5 × ULN 2. Renal function: The following criteria must be satisfied
• Creatinine clearance or glomerular filtration rate ≥ 50 mL/min 3. Respiratory function: percutaneous arterial oxygen saturation (SpO₂) ≥ 90%
• Patients who are expected to survive for at least 3 months
• Patients who give written consent to participate in the trial using the informed consent form approved by the institutional review board
• [Expansion Assessment Part]
• Patients aged 20 years or older
• Patients with a diagnosis of MDS (RA, RARS, RAEB, RAEB-T, or CMML) according to the FAB classification, who are categorized as Int-2 or high risk according to the IPSS
• Patients with an ECOG PS score of 0 or 1
• Patients with adequate organ function as indicated below
• Hepatic function: All of the following criteria must be satisfied
• Total bilirubin ≤ 2.0 ×ULN
• AST ≤ 2.5 × ULN
• ALT ≤ 2.5 × ULN 2. Renal function: The following criteria must be satisfied
• Creatinine clearance or glomerular filtration rate ≥ 50 mL/min 3. Respiratory function: percutaneous arterial oxygen saturation (SpO₂) ≥ 90%
• Patients who are expected to survive for at least 3 months
• Patients who give written consent to participate in the trial using the informed consent form approved by the institutional review board

You may not qualify if…

• [Tolerability Assessment Part]
• Patients who are unlikely to respond to AZA
• Patients who have received chemotherapy, hormone therapy, antibody therapy, radiotherapy, or other exploratory anti-cancer treatments for the primary disease within 3 weeks prior to the first administration of the investigational medicinal product (IMP)
• Patients who have used any other IMP or any privately imported medicine within 4 weeks prior to the first administration of IMP
• Patients with heart disease of Class 3 or 4 according to the New York Heart Association classification
• Patients with uncontrolled systemic disease or active infection
• Patients with uncontrolled gastric or duodenal ulcer
• Patients with prior or current interstitial lung disease
• Patients with a history of surgical gastrectomy
• Patients with life-threatening conditions/symptoms, multiple organ failure, or other factors (including laboratory abnormalities) that, in the opinion of the investigator, are likely to affect their safety or the absorption and metabolism of AZA and CED, or influence the trial evaluation
• Patients with other malignancies (except appropriately treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ; prostate or breast cancer stabilized by endocrine therapies; and malignancies that have not relapsed for at least 1 year since the last successful treatment)
• Patients who are positive for HIV antibody, HBV-DNA, or HCV antibody
• Patients with any ≥ Grade 2 AE (except alopecia) associated with prior treatment of the primary disease. However, the parameters defined in inclusion criterion 4) above are excluded.
• Patients who have undergone a highly invasive and extensive surgical procedure within 4 weeks prior to the first administration of IMP
• Patients who previously underwent hematopoietic stem cell transplantation and have evidence of graft-versus-host disease (GVHD), or who received immunotherapy within 3 weeks before the start of study treatment.
• Patients with a history of hypersensitivity to the active ingredient or any excipient of IMP
• Patients who are, in the opinion of the investigator, at high risk for being unable to comply with the trial protocol because of mental disorders or other medical conditions (alcohol/substance abuse or addiction)
• Pregnant or nursing female patients, or female patients with a positive pregnancy test at screening
• Sexually active males (except those with a history of bilateral orchiectomy) or females of childbearing potential who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 3 months (males) and 6 months (females) after the last dose of IMP
• Patients who, in the opinion of the investigator, are otherwise ineligible to participate in the trial
• [ Expansion Assessment Part]
• Patients who are unlikely to respond to AZA
• Patients who have received chemotherapy, hormone therapy, antibody therapy, radiotherapy, or other exploratory anti-cancer treatments for the primary disease within 3 weeks prior to the first administration of the IMP
• Patients who have received prior treatment with DNA methylation inhibitors, such as decitabine or AZA
• Patients who have used any other IMP or any privately imported medicine within 4 weeks prior to the first administration of IMP

Where it is running

• Nippon Medical School Hospital — Bunkyō City, Japan (enrolling)
• Fukushima Medical University Hospital — Fukushima, Japan (enrolling)
• Saitama Medical University Hospital — Iruma, Japan (enrolling)
• University Hospital, Kyoto Prefectural University of Medicine — Kyoto, Japan (enrolling)
• Nagasaki University Hospital — Nagasaki, Japan (enrolling)
• Osaka City General Hospital — Osaka, Japan (enrolling)
• Kindai University Hospital — Sakai, Japan (enrolling)
• NTT Medical Center Tokyo — Shinagawa-Ku, Japan (enrolling)
• Tokyo Medical University Hospital — Shinjuku-Ku, Japan (enrolling)
• Yamagata University Hospital — Yamagata, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.